Recombinant Interferon gamma, also known as rIFN-γ, is a therapeutic protein that is artificially synthesized using genetic engineering techniques. It is a form of Interferon gamma (IFN-γ), which is a naturally occurring immune system protein produced by certain cells in the body in response to infections, cancers, and other diseases. Recombinant Interferon gamma is similar to the naturally occurring form but is produced in larger quantities through recombinant DNA technology.
This therapeutic protein has various functions within the immune system, including activating immune cells like macrophages and natural killer cells, enhancing the production of specific cytokines, stimulating the expression of major histocompatibility complex (MHC) molecules, and modulating the immune response. These activities make it a valuable treatment option for a range of conditions, including chronic granulomatous disease, severe combined immunodeficiency, and osteopetrosis.
Recombinant Interferon gamma is typically administered via injection and is available for clinical use in formulations approved by regulatory authorities. The dosage and administration schedule may vary depending on the specific condition being treated, and it is usually prescribed and monitored by healthcare professionals. The protein can have side effects, including flu-like symptoms such as fever, fatigue, and muscle aches, as well as potential immune system reactions.
In summary, recombinant Interferon gamma is an artificially produced therapeutic protein that mimics the natural immune system protein IFN-γ. It is used to treat various diseases and conditions by modulating the immune response and enhancing immune cell activity.
